Later, the clinical efficacy of JAK1 blockade was confirmed by the improvement of vasculitic lesions and lung function in three children suffering from SAVI, treated with ruxolitinib, and in a 9-year-old boy with a SAVI vasculitis treated with tofacitinib (113, 114). This evidence concerns the gene JAK1 and STING-associated vasculopathy with onset in infancy.